NCT01412151View on ClinicalTrials.gov

Creatine Safety & Tolerability in Huntington's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Huntington's Disease (HD)
Interventions
DRUG

Creatine monohydrate

Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose

Trial Locations (1)

02129

Massachusetts General Hospital, Charlestown

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01412151 - Creatine Safety & Tolerability in Huntington's Disease | Biotech Hunter | Biotech Hunter